Caribou Biosciences (CRBU) Cash & Current Investments (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Cash & Current Investments data on file, last reported at $117.6 million in Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $117.6 million, down 43.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $117.6 million (down 43.58% YoY), and the FY2025 annual result was $139.3 million, down 33.5% from the prior year.
• Cash & Current Investments declined to $117.6 million in Q1 2026 per CRBU's latest filing, from $139.3 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $353.7 million in Q1 2022 and troughed at $117.6 million in Q1 2026.
• A 5-year average of $245.9 million and a median of $247.7 million in 2022 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2022 and 2026: Cash & Current Investments surged 738865.22% in 2022, then sank 43.58% in 2026.
• A 5-year view of Cash & Current Investments shows it stood at $247.7 million in 2022, then soared by 32.77% to $328.8 million in 2023, then tumbled by 36.28% to $209.5 million in 2024, then sank by 33.5% to $139.3 million in 2025, then slipped by 15.58% to $117.6 million in 2026.
• Business Quant data shows CRBU's Cash & Current Investments at $117.6 million in Q1 2026, $139.3 million in Q4 2025, and $147.3 million in Q3 2025.